INZY vs. NBTX, VNDA, ENTA, RAPT, HOWL, PYXS, NKTR, EPIX, AKBA, and RENB
Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Nanobiotix (NBTX), Vanda Pharmaceuticals (VNDA), Enanta Pharmaceuticals (ENTA), RAPT Therapeutics (RAPT), Werewolf Therapeutics (HOWL), Pyxis Oncology (PYXS), Nektar Therapeutics (NKTR), ESSA Pharma (EPIX), Akebia Therapeutics (AKBA), and Renovaro (RENB). These companies are all part of the "pharmaceutical preparations" industry.
Nanobiotix (NASDAQ:NBTX) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
Inozyme Pharma's return on equity of 0.00% beat Nanobiotix's return on equity.
38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 11.9% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Nanobiotix has higher revenue and earnings than Inozyme Pharma.
Nanobiotix has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Nanobiotix presently has a consensus price target of $11.00, suggesting a potential upside of 86.13%. Inozyme Pharma has a consensus price target of $17.00, suggesting a potential upside of 292.61%. Given Nanobiotix's higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Nanobiotix.
In the previous week, Nanobiotix had 1 more articles in the media than Inozyme Pharma. MarketBeat recorded 1 mentions for Nanobiotix and 0 mentions for Inozyme Pharma. Inozyme Pharma's average media sentiment score of 0.00 equaled Nanobiotix'saverage media sentiment score.
Inozyme Pharma received 24 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 80.49% of users gave Inozyme Pharma an outperform vote while only 60.00% of users gave Nanobiotix an outperform vote.
Summary
Inozyme Pharma beats Nanobiotix on 7 of the 12 factors compared between the two stocks.
Get Inozyme Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inozyme Pharma Competitors List
Related Companies and Tools
